Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease.

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data, following a pattern of big pharma partners ending collaborations. Current hemophilia A market ...

Williamsville struggled shooting against Auburn for a fifth straight quarter, but unlike the January Sangamon County ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT Astellas Pharma Inc. (TSE ...

Auburn, IL. (WICS) — With their regular-season finale on Friday Williamsville finished the regular season undefeated in ...

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...